Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-15-transpresenting WT1-targeted autologous dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Antwerp University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The **IL-15-transpresenting WT1-targeted autologous dendritic cell vaccine** (also known as the **IL15/IL15Ra/WT1 DC vaccine**) is an investigational, personalized cell-based immunotherapy developed by Antwerp University Hospital. It consists of autologous monocyte-derived dendritic cells engineered via electroporation with messenger RNA (mRNA) encoding both interleukin-15 (IL-15) and interleukin-15 receptor alpha (IL-15Rα) to transpresent IL-15 on their cell surface, alongside presentation of the Wilms' Tumor Protein 1 (WT1) antigen. This dual mechanism is designed to enhance the immunogenicity of the dendritic cells, boosting natural killer (NK) and CD8+ T cell activation and survival while directing a cytotoxic immune response specifically against WT1-expressing cancer cells. The vaccine is currently being evaluated in a Phase 1 first-in-human clinical trial (NCT05964361) for patients with advanced or refractory solid tumors of the pancreas, esophagus, liver, and ovaries.
- Other names
- IL15/IL15Ra/WT1 DC vaccineIL15-transpresenting WT1-targeting DC vaccineIL-15-transpresenting WT1-targeting DC vaccineIL 15-transpresenting WT1-targeting DC vaccineIL-15-transpresenting WT1-targeting autologous dendritic cell vaccineIL15-transpresenting WT1-targeting autologous dendritic cell vaccineIL 15-transpresenting WT1-targeting autologous dendritic cell vaccine
02
Targets
IL15 (Interleukin 15)IL15RA (Interleukin-15 receptor subunit alpha)WT1-pMHC (Wilms tumor protein-derived peptide-major histocompatibility complex (WT1-pMHC) recognized by T-cell receptors)
Beyond the preview
Go deeper on IL-15-transpresenting WT1-targeted autologous dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-15-transpresenting WT1-targeted autologous dendritic cell vaccine.